» Articles » PMID: 19623293

Hereditary Cancer Syndromes

Overview
Date 2009 Jul 23
PMID 19623293
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Persons carrying mutations for hereditary cancer syndromes are at high risk for the development of tumors at an early age, as well as the synchronous or metachronous development of multiple tumors of the corresponding tumor spectrum. The genetic causes of many hereditary cancer syndromes have already been identified. About 5% of all cancers are part of a hereditary cancer syndrome.

Methods: Selective literature review, including evidence-based guidelines and recommendations.

Results: Clinical criteria are currently available according to which many hereditary cancer syndromes can be diagnosed or suspected and which point the way to further molecular genetic analysis. A physician can easily determine whether these criteria are met by directed questioning about the patient's personal and family medical history. The identification of the causative germ line mutation in the family allows confirmation of the diagnosis in the affected individual and opens up the option of predictive testing in healthy relatives.

Discussion: Mutation carriers for hereditary cancer syndromes need long-term medical surveillance in a specialized center. It is important that these persons should be identified in the primary care setting and then referred for genetic counseling if molecular genetic testing is to be performed in a targeted, rational manner.

Citing Articles

Enhancing Cancer Screening and Early Diagnosis in India: Overcoming Challenges and Leveraging Emerging Technologies.

Mangayarkarasi V, Durairaj E, Ramanathan V Cureus. 2025; 17(2):e78808.

PMID: 40078237 PMC: 11902917. DOI: 10.7759/cureus.78808.


Exome-based cancer predisposition gene testing can provide a genetic diagnosis for individuals with heterogeneous tumor phenotypes.

Hinic S, Mensenkamp A, Schuurs-Hoeijmakers J, Brugnoletti F, Vreede L, van Veen E Eur J Hum Genet. 2025; .

PMID: 39979679 DOI: 10.1038/s41431-025-01814-z.


Pediatric Tumors as Disorders of Development: The Case for In Vitro Modeling Based on Human Stem Cells.

Clairmont C, Gell J, Lau C Cancer Control. 2024; 31:10732748241270564.

PMID: 39118322 PMC: 11311176. DOI: 10.1177/10732748241270564.


Cascade testing for hereditary cancer in Singapore: how population genomics help guide clinical policy.

Caeser R, Chiang J, Tan E, Tai E, Ngeow J Fam Cancer. 2024; 23(2):133-140.

PMID: 38662262 DOI: 10.1007/s10689-024-00376-1.


Strategies to improve implementation of cascade testing in hereditary cancer syndromes: a systematic review.

Chiang J, Chua Z, Chan J, Sule A, Loke W, Lum E NPJ Genom Med. 2024; 9(1):26.

PMID: 38570510 PMC: 10991315. DOI: 10.1038/s41525-024-00412-0.


References
1.
Walsh T, Casadei S, Coats K, Swisher E, Stray S, Higgins J . Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006; 295(12):1379-88. DOI: 10.1001/jama.295.12.1379. View

2.
Le Bihan C, Moutou C, Brugieres L, Feunteun J, Bonaiti-Pellie C . ARCAD: a method for estimating age-dependent disease risk associated with mutation carrier status from family data. Genet Epidemiol. 1995; 12(1):13-25. DOI: 10.1002/gepi.1370120103. View

3.
Lamberti C, Mangold E, Pagenstecher C, Jungck M, Schwering D, Bollmann M . Frequency of hereditary non-polyposis colorectal cancer among unselected patients with colorectal cancer in Germany. Digestion. 2006; 74(1):58-67. DOI: 10.1159/000096868. View

4.
Thull D, Vogel V . Recognition and management of hereditary breast cancer syndromes. Oncologist. 2004; 9(1):13-24. DOI: 10.1634/theoncologist.9-1-13. View

5.
Antoniou A, Pharoah P, McMullan G, Day N, Ponder B, Easton D . Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol. 2001; 21(1):1-18. DOI: 10.1002/gepi.1014. View